Spinnaker Life Sciences Strategy Consulting’s Post

Although I agree that Medtronic has been slow to invest in the SNM market, it's important to acknowledge that competition shouldn't be allowed to use their patents because of a perceived lack of innovation. The stakes are high and it will be interesting to see how this all plays out. https://lnkd.in/eCqW3tiR #sacralnervestimulation #pns #urinaryincontinence #fecalincontinence #neuromodulation #lawsuit #sns #urgeincontinence #implantable

Johnson & Johnson (JNJ.N), on Friday agreed to buy Shockwave Medical (SWAV.O), in a deal valued at $13.1 billion including debt, as it builds its cardiac-health-centric medical devices business to help drive growth. J&J has offered $335 per share in cash that values the equity portion at $12.5 billion. The offer also represents a 17% premium to the stock's closing price in late March, when the Wall Street Journal reported J&J's interest in Shockwave, whose shares were currently trading at $326.82. The acquisition gives J&J access to a device that uses shockwaves to break down calcified plaque in heart vessels, similar to how kidney stones are treated. RBC analysts estimate the total addressable market for similar therapies at about $10 billion. It is also the latest in a string of takeovers that focuses on building its cardiac health division - after a $16.6 billion deal to buy heart pump maker Abiomed in 2022 and a $400 million bid for heart-centric device maker Laminar. "Shockwave checks all the boxes" from an M&A perspective, J&J CEO Joaquin Duato said on a conference call. J&J reiterated that it would focus on deals that add value to its cardiovascular product portfolio. J&J is trying to bolster its medical devices business as it gears up to face fresh U.S. competition for its blockbuster Crohn's disease drug, Stelara, from next year. With the latest deal, J&J is entering an "opportunistic space," CRISPidea analyst Shejal Ajmera said. "I would certainly like to see how aggressively they will be turning this into a revenue source. Shockwave's catheter-based treatment known as intravascular lithotripsy (IVL) is used, often in combination with stents, to treat two common heart conditions. Shockwave posted product sales of $730.2 million last year. J&J expects to finance the deal through a combination of cash on hand and debt. It expects that the deal will reduce its adjusted earnings per share by 10 cents this year.

Great insights here from Niall Cullen

Really interesting article published by Chris Newmarker from MassDevice highlights the top medtech stories of the year so far. In a year full of exciting M&A's, I agree with the author's view that the rise of pulsed-field ablation in the US takes the top spot. Given the numerous FDA approvals in PFA for Medtronic, Boston Scientific and Johnson & Johnson coupled with Abbott first global procedures for its Volt system, PFA really has been the centre of attention within the #Epeeps community. What MedTech stories of the year interested you the most? #medtech #medicaldevices #pfa

Major medtech M&A news this morning: Johnson & Johnson has agreed to acquire Shockwave Medical for approximately $13.1 billion. The deal values Shockwave at $335 per share. Both companies’ boards have approved the transaction, and J&J expects the deal to close in mid-2024. Shockwave makes medical devices that break up calcium deposits in coronary arteries using sound pressure waves, a technique called intravascular lithotripsy. The company forecast a sales range of from $910 million to $930 million for 2024, and had $990.6 million in cash or cash equivalents as of Dec. 31. J&J has recently had a run of medtech M&A: The company purchased Laminar for $400 million in November and Abiomed for $16.6 billion in 2022.

𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗥𝗲𝗮𝗰𝗵 $149.4 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 2029𝗅 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲-https://lnkd.in/dJvgj2zb The size of global medical device contract manufacturing market in terms of revenue was estimated to be worth $78.9 billion in 2024 and is poised to reach $149.4 billion by 2029, growing at a CAGR of 11.4% from 2024 to 2029. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝗠𝗮𝗿𝗸𝗲𝘁 Medical Device Manufacturing St. Jude Medical Zimmer Biomet Arthrex Applied Medical Wright Medical Avanos Medical Inari Medical Confluent Medical Technologies Argon Medical Devices, Inc. Cirtec Medical Nalu Medical, Inc. Greatbatch Medical Paragon Medical Nissha Medical Technologies      Heraeus Medical Components   Vention Medical ForTec Medical, Inc. Lake Region Medical Harmac Medical Products Norwood Medical Medpace STERIS ClinChoice Orthofix Insulet Corporation MicroVention-Terumo Nevro Glidewell Dental Alphatec Spine Integer Holdings Corporation   Cutera, Inc. Verathon TekniPlex Sciton Biomerics AtriCure, Inc.  Acumed Resonetics Azzur Group

𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗗𝗲𝘃𝗶𝗰𝗲 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗥𝗲𝗮𝗰𝗵 $149.4 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 2029𝗅 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲-https://lnkd.in/dJvgj2zb The size of global medical device contract manufacturing market in terms of revenue was estimated to be worth $78.9 billion in 2024 and is poised to reach $149.4 billion by 2029, growing at a CAGR of 11.4% from 2024 to 2029. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝗠𝗮𝗿𝗸𝗲𝘁 Medical Device Manufacturing St. Jude Medical Zimmer Biomet Arthrex Applied Medical Wright Medical Avanos Medical Inari Medical Confluent Medical Technologies Argon Medical Devices, Inc. Cirtec Medical Nalu Medical, Inc. Greatbatch Medical Paragon Medical Nissha Medical Technologies      Heraeus Medical Components   Vention Medical ForTec Medical, Inc. Lake Region Medical Harmac Medical Products Norwood Medical Medpace STERIS ClinChoice Orthofix Insulet Corporation MicroVention-Terumo Nevro Glidewell Dental Alphatec Spine Integer Holdings Corporation   Cutera, Inc. Verathon TekniPlex Sciton Biomerics AtriCure, Inc.  Acumed Resonetics Azzur Group

Efficiency increase of the strategic distribution of medical devices in Europe for SMEs Many medical device companies aim to sell their products on European markets. Their own budget bottlenecks allow only limited market opportunities. What are the reasons and what considerations should SMEs make to increase the efficiency of the strategic distribution of their medical devices? https://lnkd.in/e3GWzA-d

Route 92 Medical, Inc. has achieved a significant milestone by securing CE Approval for its innovative neurovascular intervention products under the EU Medical Device Regulation (MDR) 2017/745, along with clearance under the MDSAP program.   This achievement marks a pivotal step in the company’s mission to enhance patient outcomes during neurovascular interventions and opens doors to international markets   🌍 Tony Chou, M.D., founder and CEO of Route 92 Medical, emphasized that this certification not only facilitates entry into the European market but also lowers regulatory barriers for other regions.   The company’s product portfolio includes advanced reperfusion systems such as the HiPoint and FreeClimb series, which are designed to improve the efficiency of procedures for treating acute ischemic strokes   🧠 Dr Francesco Massari, MD, MSc, PhD, a leading neurointerventionalist, highlighted the importance of these new tools, stating that they provide clinicians with improved methods to navigate the complex neurovasculature and effectively remove clots without the need for guidewires. This innovation is expected to enhance procedural efficiency and patient outcomes significantly.   ✨With over 100 patents covering its products, Route 92 Medical is poised to become a key player in the neurovascular intervention market. As they focus on commercializing their offerings in Europe, the company remains committed to collaborating with top neurovascular clinicians to overcome challenges in the field and deliver impactful solutions. 🚀 https://lnkd.in/eYjWuzMt #Neurovascular #CEMark #MDR #MedTech #IschemicStroke

Policy | In April, the recent release of the 2024 medical device classification encompasses 223 results, including 93 products related to #IVD. Among these, 27 IVD-related products are suggested for Class III medical device management, 45 for Class II, and 14 for Class I. In July 2023, the National Medical Products Administration (NMPA) issued the Opinions to further emphasize the significance of classification management in overseeing medical devices. As the medical device industry advances rapidly, regulatory efforts face new challenges and demands. For further information, please view: https://lnkd.in/gUn3QSb5 #medicladevice #medicalequipment #regulation #catalogue #diagnostics #China